The Cystic Fibrosis Foundation announced the recipients of its sixth annual Impact Grants.
Site Search
Marissa Benchea and Jeremy and Rachel Olimb to lead the Foundation’s volunteer advocacy base into a new chapter of CF
The Cystic Fibrosis Foundation awarded up to $4.7 million to EnBiotix Inc. to study the potential use of inhaled colistin as an additional option to treat Pseudomonas infections in people with cystic fibrosis who are not responding to current treatments.
The Cystic Fibrosis Foundation awarded up to $3.5 million to Arrevus Inc. to test a potential treatment for pulmonary exacerbations in people with cystic fibrosis in a late phase clinical trial.
New funding awards include up to $2.6M to Eloxx Pharmaceuticals to identify potential therapies for CF nonsense mutations
This milestone was reached nearly two years ahead of the initiative’s five-year commitment. However, the Foundation aims to continue to support infection research at the same pace as it has in the past three years.
Today, the Cystic Fibrosis Foundation announced a collaboration with Deep Science Ventures to accelerate treatments that address the underlying cause of CF for every person with the disease. The collaboration will focus on uncovering and designing new technologies to address key scientific challenges on the Path to a Cure.
The Foundation, in collaboration with external community advisors, finalizes recommendations in area of Community to help foster more inclusion and improve the experiences of Black people living with and impacted by cystic fibrosis.
Foundation welcomes new members to advance its mission
A transformative leader for more than two decades, Marshall will transition to advisory role